Literature DB >> 21206133

Intestinal absorption of HMG-CoA reductase inhibitor pitavastatin mediated by organic anion transporting polypeptide and P-glycoprotein/multidrug resistance 1.

Yoshiyuki Shirasaka1, Kensuke Suzuki, Megumi Shichiri, Takeo Nakanishi, Ikumi Tamai.   

Abstract

The purpose of this study was to investigate the involvement of organic anion transporting polypeptide (OATP/Oatp) and P-glycoprotein (P-gp)/multidrug resistance 1 (MDR1/Mdr1) in intestinal absorption of pitavastatin. Pitavastatin was found to be a substrate for human OATP1A2, OATP2B1, and MDR1 and rat Oatp1a5, Oatp2b1, and Mdr1a in experiments using transporter-expressing Xenopus oocytes and LLC-PK1 cell systems. Naringin inhibited Oatp1a5- and Mdr1a-mediated transport of pitavastatin with IC(50) values of 18.5 and 541 µM, respectively. The difference in the IC(50) values of naringin for Oatp1a5 and Mdr1a-mediated pitavastatin transport may account for the complex concentration-dependent effect of naringin on the intestinal absorption of pitavastatin. Rat intestinal permeability of pitavastatin measured by the in situ closed-loop perfusion method was indeed significantly reduced by 200 µM naringin, but was significantly increased by 1000 µM naringin. Furthermore, the permeability was significantly increased by elacridar, a potent inhibitor of Mdr1, while the permeability was significantly decreased in the presence of both elacridar and naringin, suggesting that Oatp1a5 and Mdr1a are both involved in intestinal absorption of pitavastatin. Our present results indicate that OATP/Oatp and MDR1/Mdr1 play roles in the intestinal absorption of pitavastatin as influx and efflux transporters, respectively.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21206133     DOI: 10.2133/dmpk.dmpk-10-rg-073

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  12 in total

1.  Substrate- and dose-dependent drug interactions with grapefruit juice caused by multiple binding sites on OATP2B1.

Authors:  Yoshiyuki Shirasaka; Takanori Mori; Yukiko Murata; Takeo Nakanishi; Ikumi Tamai
Journal:  Pharm Res       Date:  2014-02-19       Impact factor: 4.200

Review 2.  Transporters at CNS barrier sites: obstacles or opportunities for drug delivery?

Authors:  Lucy Sanchez-Covarrubias; Lauren M Slosky; Brandon J Thompson; Thomas P Davis; Patrick T Ronaldson
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 3.  P-glycoprotein trafficking as a therapeutic target to optimize CNS drug delivery.

Authors:  Thomas P Davis; Lucy Sanchez-Covarubias; Margaret E Tome
Journal:  Adv Pharmacol       Date:  2014-08-23

Review 4.  Pediatric Statin Administration: Navigating a Frontier with Limited Data.

Authors:  Jonathan Wagner; Susan M Abdel-Rahman
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Sep-Oct

Review 5.  Targeted drug delivery to treat pain and cerebral hypoxia.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Pharmacol Rev       Date:  2013-01-23       Impact factor: 25.468

Review 6.  Organic anion-transporting polypeptides.

Authors:  Bruno Stieger; Bruno Hagenbuch
Journal:  Curr Top Membr       Date:  2014       Impact factor: 3.049

7.  Comparative Study of the Dose-Dependence of OATP1B Inhibition by Rifampicin Using Probe Drugs and Endogenous Substrates in Healthy Volunteers.

Authors:  Issey Takehara; Takashi Yoshikado; Keiko Ishigame; Daiki Mori; Ken-Ichi Furihata; Nobuaki Watanabe; Osamu Ando; Kazuya Maeda; Yuichi Sugiyama; Hiroyuki Kusuhara
Journal:  Pharm Res       Date:  2018-05-10       Impact factor: 4.200

8.  Genomewide Association Study of Statin-Induced Myopathy in Patients Recruited Using the UK Clinical Practice Research Datalink.

Authors:  Daniel F Carr; Ben Francis; Andrea L Jorgensen; Eunice Zhang; Hector Chinoy; Susan R Heckbert; Joshua C Bis; Jennifer A Brody; James S Floyd; Bruce M Psaty; Mariam Molokhia; Maryse Lapeyre-Mestre; Anita Conforti; Ana Alfirevic; Tjeerd van Staa; Munir Pirmohamed
Journal:  Clin Pharmacol Ther       Date:  2019-07-31       Impact factor: 6.875

9.  Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs.

Authors:  Pengfei Jiang; Rajesh Mukthavaram; Rajesh Mukthavavam; Ying Chao; Ila Sri Bharati; Valentina Fogal; Sandra Pastorino; Xiuli Cong; Natsuko Nomura; Matt Gallagher; Taher Abbasi; Shireen Vali; Sandeep C Pingle; Milan Makale; Santosh Kesari
Journal:  J Transl Med       Date:  2014-01-17       Impact factor: 5.531

10.  Pharmacokinetic parameters of ifosfamide in mouse pre-administered with grapefruit juice or naringin.

Authors:  Eduardo Madrigal-Bujaidar; Edilberto Pérez-Montoya; Sandra García-Medina; José Melesio Cristóbal-Luna; José A Morales-González; Eduardo Osiris Madrigal-Santillán; Rogelio Paniagua-Pérez; Isela Álvarez-González
Journal:  Sci Rep       Date:  2019-11-12       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.